TickerGuard
Buy Day today: Neutral (46) Mixed market breadth · no major macro event
GANX

Gain Therapeutics Inc

Healthcare · Biotechnology

1.10$ -4.2% vs. previous close Closing price · As of: Oct 30, 2026

Ownership

Ownership Structure

Who owns Gain Therapeutics Inc (GANX)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 97.7% of the shares are freely tradable; institutional investors hold 19.2%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 19.2%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 2.3%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 97.7%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 7.2%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 44Mio.

Largest Shareholders

Institutions

Institutions GANX
Name Stake (%) Shares Change (%) Date
Marshall Wace Asset Management Ltd 4.41 1,923,546 +8.7 06/30/2026
CAMBRIDGE Invest RESEARCH ADVISORS, INC. 2.61 1,137,290 +100.0 06/30/2026
Potomac Capital Management, Inc. 2.17 946,400 -6.2 06/30/2026
GSA Capital Partners LLP 1.45 632,131 +102.3 06/30/2026
JONES FINANCIAL COMPANIES LLLP 1.39 608,592 -3.6 06/30/2026
Vanguard Capital Management, LLC 1.10 480,269 +20.1 06/30/2026
Geode Capital Management, LLC 1.04 453,501 +1.4 06/30/2026
BlackRock Inc 0.63 274,957 +22.2 06/30/2026
Vanguard Fiduciary Trust Co 0.53 231,534 +0.7 06/30/2026

Funds

Funds GANX
Name Stake (%) Shares Change (%) Date
BANOR SICAV Rosemary S EUR Acc 0.57 250,100 +108.4 06/30/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: October 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?